Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy Rating

Acrivon Therapeutics, Inc. (ACRV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on the stock and has a $7.00 price target.

Michael Okunewitch’s rating is based on Acrivon Therapeutics’ promising clinical developments and strategic focus. The company is advancing its ACR-368 program, which targets CHK1/2, a crucial regulator in DNA damage response pathways, showing potential for synthetic lethality and tumor cell death. Acrivon has refined its approach by using an OncoSignature assay to better select patients likely to respond, resulting in improved objective response rates compared to previous studies.
Additionally, Acrivon’s pipeline is bolstered by the internally developed ACR-2316 program, which has shown clinical activity without safety concerns in early dose levels. The company’s strategic decision to focus on endometrial cancer, where strong interim results were observed, and its continued pipeline expansion with a novel cell cycle drug expected in 2025, further support the Buy rating. The favorable safety profile and disease control rates in severe patient populations add to the positive outlook for Acrivon’s therapeutic candidates.

In another report released on May 15, H.C. Wainwright also maintained a Buy rating on the stock with a $19.00 price target.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACRV in relation to earlier this year.